Shankha Satpathy,Karsten Krug,Pierre M. Jean Beltran,Sara R. Savage,Francesca Petralia,Chandan Kumar-Sinha,Yongchao Dou,Boris Reva,M. Harry Kane,Shayan C. Avanessian,Suhas V. Vasaikar,Azra Krek,Jonathan T. Lei,Eric J. Jaehnig,Tatiana Omelchenko,Yifat Geffen,Erik J. Bergstrom,Vasileios Stathias,Karen E. Christianson,David I. Heiman,Marcin P. Cieslik,Song Cao,Xiaoyu Song,Jiayi Ji,Wenke Liu,Kai Li,Bo Wen,Yize Li,Zeynep H. Gümüş,Myvizhi Esai Selvan,Rama Soundararajan,Tanvi H. Visal,Maria G. Raso,Edwin Roger Parra,Özgün Babur,Pankaj Vats,Shankara Anand,Tobias Schraink,MacIntosh Cornwell,Fernanda Martins Rodrigues,Houxiang Zhu,Chia-Kuei Mo,Yuping Zhang,Felipe da Veiga Leprevost,Chen Huang,Arul M. Chinnaiyan,Matthew A. Wyczalkowski,Gilbert S. Omenn,Chelsea J. Newton,Stephan Schurer,Kelly V. Ruggles,David Fenyö,Scott D. Jewell,Mathangi Thiagarajan,Mehdi Mesri,Henry Rodriguez,Sendurai A. Mani,Namrata D. Udeshi,Gad Getz,James Suh,Qing Kay Li,Galen Hostetter,Paul K. Paik,Saravana M. Dhanasekaran,Ramaswamy Govindan,Li Ding,Ana I. Robles,Karl R. Clauser,Alexey I. Nesvizhskii,Pei Wang,Steven A. Carr,Bing Zhang,D.R. Mani,Michael A. Gillette,Clinical Proteomic Tumor Analysis Consortium,Alex Green,Alfredo Molinolo,Alicia Francis,Amanda G. Paulovich,Andrii Karnuta,Antonio Colaprico,Barbara Hindenach,Barbara L. Pruetz,Bartosz Kubisa,Brian J. Druker,Carissa Huynh,Charles A. Goldthwaite,Chet Birger,Christopher R. Kinsinger,Corbin D. Jones,Dan Rohrer,Dana R. Valley,Daniel W. Chan,David Chesla,Donna Hansel,Elena V. Ponomareva,Elizabeth Duffy,Eric Burks,Eric E. Schadt,Eugene S. Fedorov,Eunkyung An,Fei Ding,George D. Wilson,Harsh Batra,Hui Zhang,Jennifer E. Maas,Jennifer Eschbacher,Karen A. Ketchum,Karin D. Rodland,Katherine A. Hoadley,Kei Suzuki,Ki Sung Um,Liqun Qi,Lori Bernard,Maciej Wiznerowicz,Małgorzata Wojtyś,Marcin J. Domagalski,Matthew J. Ellis,Maureen A. Dyer,Melissa Borucki,Meenakshi Anurag,Michael J. Birrer,Midie Xu,Mikhail Krotevich,Nancy Roche,Nathan J. Edwards,Negin Vatanian,Neil R. Mucci,Nicollette Maunganidze,Nikolay Gabrovski,Olga Potapova,Oluwole Fadare,Pamela Grady,Peter B. McGarvey,Pushpa Hariharan,Ratna R. Thangudu,Rebecca Montgomery,Renganayaki Pandurengan,Richard D. Smith,Robert J. Welsh,Sailaja Mareedu,Samuel H. Payne,Sandra Cottingham,Shilpi Singh,Shirley X. Tsang,Shuang Cai,Stacey Gabriel,Tao Liu,Tara Hiltke,Tanmayi Vashist,Thomas Bauer,Volodymyr Sovenko,Warren G. Tourtellotte,Weiping Ma,William Bocik,Wohaib Hasan,Xiaojun Jing,Ximing Tang,Yuxing Liao,Yvonne,Shutack,Zhen Zhang,Ziad Hanhan

Abstract:Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications. We identify NSD3 as an alternative driver in FGFR1-amplified tumors and low-p63 tumors overexpressing the therapeutic target survivin. SOX2 is considered undruggable, but our analyses provide rationale for exploring chromatin modifiers such as LSD1 and EZH2 to target SOX2-overexpressing tumors. Our data support complex regulation of metabolic pathways by crosstalk between post-translational modifications including ubiquitylation. Numerous immune-related proteogenomic observations suggest directions for further investigation. Proteogenomic dissection of CDKN2A mutations argue for more nuanced assessment of RB1 protein expression and phosphorylation before declaring CDK4/6 inhibition unsuccessful. Finally, triangulation between LSCC, LUAD, and HNSCC identified both unique and common therapeutic vulnerabilities. These observations and proteogenomics data resources may guide research into the biology and treatment of LSCC.

Supplementary Figures 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Supplementary Figure Legends 1-7 from Mutations in the <i>ddr2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Data from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Interview with Dr. Meyerson from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients

Identification Of Genetic Mutations In Human Lung Cancer By Targeted Sequencing

A proteogenomic portrait of lung squamous cell carcinoma

Functional Analysis of Receptor Tyrosine Kinase Mutations in Lung Cancer Identifies Oncogenic Extracellular Domain Mutations of Erbb2

Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Title : Targeting HER 2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel 2 Tyrosine Kinase Inhibitor